 ii
  
中文摘要 
目前我們已完成文獻中攸關行為異常相關基因 (Gβ3、InFG、
ADA、DRD2A、DRD2β、HTR2A、COMT、ADRA1R、DRD3) 的
基因分析方法，且已完成控制組的分析實驗。檢體收集已完成部分梗
賡續收集中，期盼能完成足夠及具有統計意義的檢體數目，盼望下期
計畫能持續進行，可以順利完成全部檢體收集與實驗分析程序，達成
最初執行本計畫之目標。 
 
關鍵字：安全基因，降低職災，安全管理 
 iv
目       錄 
中文摘要 ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥ ii 
英文摘要 ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥ iii 
目錄 ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥ iv 
表目錄 ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥ v 
圖目錄 ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥ vii-viii 
 前言      ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥ 1 
 研究目的      ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥ 2 
 文獻探討      ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥ 2 
 研究方法      ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥ 4 
 結果與討論    ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥ 4 
 研究成果      ‥‥‥‥‥‥‥‥‥‥‥‥‥‥‥ 6 
附件   
 附件一 檢體資料 ‥‥‥‥‥‥‥‥‥‥‥‥‥‥ 11 
 附件二 血液、頭髮及唾液之 DNA 萃取方法 15 
 附件三 選定之 19 種基因      ‥‥‥‥‥‥‥‥ 20 
 附件四 130 個實驗分析結果     ‥‥‥‥‥‥‥ 32 
 附件五 基因選擇之參考資料    ‥‥‥‥‥‥‥ 41 
 附件六 Primer List         ‥‥‥‥‥‥‥‥‥ 49 
 附件七 罹職災者檢體分析結果     ‥‥‥‥‥‥ 49-56 
   
 vi
表 21 Prevalence of C/C, C/T, and T/T genotypes 39 
表 22 Frequency of the C and T allele 39 
表 23 Prevalence of A/A, G/G and A/G genotypes 40 
表 24 Frequency of the A and G allele 40 
表 25 Prevalence of T/T, T/C, and C/C genotypes 49 
表 26 Frequency ofthe T and C allele 49 
表 27 Prevalence of M/M, M/N, and N/N genotypes  50 
表 28 Frequency ofthe M and N allele 50 
表 29 Prevalence of A1/A1, A1/A2, and A2/A2 genotypes 51 
表 30 Frequency of the A1 and A2 allele 51 
表 31 Prevalence of B1/B1, B1/B2, and B2/B2 genotypes  52 
表 32 Frequency ofthe B1 and B2 allele 52 
表 33 Prevalence of T/T, T/C, and C/C genotypes  53 
表 34 Frequency of the T and C allele 53 
表 35 Prevalence of H/H, H/L, and L/L genotypes 54 
表 36 Frequency ofthe H and L allele 54 
表 37 Prevalence of C/C, C/T, and T/T genotypes 55 
表 38 Frequency ofthe C and T allele 55 
表 39 Prevalence of A/A, G/G and A/G genotypes  56 
表 40 Frequency of the A and G allele 56 
 
 viii
圖 12 The Polymerase chain reaction (PCR) amplification of 
region downstream from the polyadenylation signal 51 
圖 13 The Polymerase chain reaction (PCR) amplification of 
region downstream from the polyadenylation signal 52 
圖 14 Primer flanking the 5-HTR2A polymorphic site at 
position 102 wre use to generate a 342 bp fragment 53 
圖 15 The Polymerase chain reaction (PCR) amplification of 
exon 4 of the COMT gene 54 
圖 16 The Polymerase chain reaction (PCR) amplification of 
α1a-adrenoceptor genotype 55 
圖 17 The Polymerase chain reaction (PCR) amplification of 
region downstream from the polyadenylation signal 56 
  
 
 2
研究目的 
隨著生物科技的長足發展，生物晶片 biochips 之技術日新月異，基因分析
成本大幅降低（cost），而其分析效率相對地大幅度提高（time），因此，可藉由
此研究結果，對特定作業環境之員工進行基因分析，避免將具此特定基因之員
工，安置於有高度工作安全敏感性的職位，並針對具此特定基因之員工們，加強
安全教育訓練，以降低工安事故的發生。 
 
文獻探討 
1.安全與行為 
早於 1913 年 Watson 就提出「行為」的觀念，他認為應該把重點放在「可
觀察」的行為上（Watson, 1913），此觀念為以行為為基準的安全觀念
（behavior-based safety, BBS）提供最早的基礎。Heinderich 於 1931 年提出百分
之八十八的所有工安事故，是由於不安全的行為所造成，並建議安全管理應著
重於行為上，以降低工安事故的發生（Petersen, 2000）。Pollina 則在 1962 年以
品質管制的觀念，提出安全行為取樣的方法（Pollina, 1962），曾被成功地應用
在重型製造業，但目前已甚少被使用。在過去的十年來，以行為為基準的安全
觀念，被非常廣泛地討論，並已廣泛的被接受（Krause, 1990；Loafmann, 1998；
Geller, 2000）。 
根據美國職業安全衛生署（OSHA）的國家職業安全衛生研究所（National 
Institute for Occupational Safety and Health）之國家安全資料庫（NASD）的資料
顯示，美國有百分之八十五至九十八的所有工安事故，皆是由於員工不安全的
行為所造成（NIOSH, 1999），此資料為工安事故與行為間的關係，提供最佳的
佐證。 
2.回饋缺乏症（Reward Deficiency Syndrome） 
衝動性、成癮性及強迫性異常行為（ impulsive- addictive- compulsive 
disorder）IACD，造成無數的衝動及成癮行為，包括：酒精中毒（Blum, et al, 
1990）、多種毒藥物的濫用（Blum, et al., 1989）、抽煙（Noble, 1994）、過食症（Blum, 
Braverman, TJH Chen et. al., 1996）、過動兒 （attention deficit hyperactivity 
disorder，ADHD)（Blum, Lubar, TJH Chen et. al）以及病理性賭癮（pathological 
 4
基因關聯性研究室」之後，所欲從事的研究「工安事故與特定基因之關聯
性探討」，係屬創新的研究，即使是世界先進各國仍無類似的研究結果。 
 
研究方法 
1.檢體資料系統之構建 
根據本計劃相關行為的背景資料建構一套問卷系統，如附件一。 
2. PCR 分析技術之發展 
利用各種不同檢體來源，發展出血液、頭髮及口腔唾液檢體之 DNA 
萃取方法的機會，進行 PCR 的測試，並訓練了相關人員的分析技術，至
今已進行上百個檢體分析，技術人員之技術已經相當純熟，可進行更多
基因更多檢體之撿測。詳細的實驗方法請參考附件二。 
3. 選定基因，進行檢驗方法建立 
針對 Impulsive-addictive-compulsive behaviors 攸關之基因，進行篩
選，確定十九種目標基因，它們的 Primers、分析方法及參考資料，詳見
附件三、附件五及附件六。基因的檢測方法及基因型的發生率，結果參
照附件四。 
4.檢體之蒐集、訪談與分析工作 
完成分析方法之建立後，收集、訪談與分析工作，實驗結果相當不
錯，附件中列有部分圖示結果，並有 115 之結果彙整。同時，亦已針對
不同來源之檢體，包括：血液、頭髮及唾液發展出不同檢體的相關 DNA
之檢測萃取方法。詳細之萃取方法敬請參閱附件二。 
 
初步結果與討論 
1. General population Control 
本研究得到的 General population Control 的結果與文獻中記載的結果幾乎完
全一致，在實驗誤差範圍之內。 
2. Super Control 
Super Control 由於最後結果因問卷重新更正簡化，以因應 IRB 委員之要求，
 6
B2/B2=35.7%, B1=40.5%, B2=59.5% ；  Samples, B1/B1=0.0%, B1/B2 
=87.5%, B2/B2=12.5%, B1=43.8%, B2=56.3%.顯示有工安事故的檢體，其
B1/B2 的頻率亦遠高於控制組，相信，同樣的如果再對照 Super Control
結果將會更顯著。 
e. HTR2A Gene： HTR2A Gene 也顯現出相當差異的結果，敬請參見表 17、
表 18、表 33 及表 34；general control, T/T=40.8%, T/C=45.4%, C/C=13.9%, 
T=63.5%, C=36.5% ； Samples, T/T=75.0%, T/C=12.5%, C/C=12.5%, 
T=81.3%, C=18.8%. 
f. Gene COMT： 無明顯差異，敬請參見表 19、表 20、表 35 及表 36；general 
control, H/H=62.0%, H/L=17.1%, L/L=7.0%, H=70.5%, L=15.5%；Samples, 
H/H=75.0%, H/L=12.5%, L/L=12.5%, H=81.3%, L=18.8%. 
g. Gene ADR1A： 無明顯差異，敬請參見表 21、表 22、表 37 及表 38；general 
control, C/C=84.6%, C/T=15.4%, T/T=0.0%, C=92.3%, T=7.7%；Samples, 
C/C=100.0%, C/T=0.0%, T/T=0.0%, C=100.0%, T=0.0%. 
h. DRD3 Gene： DRD3 Gene 也顯現出相當差異的結果，敬請參見表 23、表
24、表 39 及表 40；general control, A/A=55.8%, A/G=7.0%, G/G=37.2%, 
A=74.4%, G=25.6% ； Samples, A/A=50.0%, A/G=50.0%, G/G=50.0%, 
A=50.0%, G=50.0%. 
由上述結果可看出，DRD2A Gene、DRD2βGene、HTR2A Gene 及 DRD3 
Gene 君顯現出相當程度的差異。應是未來更進 一步研究的方向。 
5. IRB 之延擱 
第一次申請本計畫 IRB 審查，竟然經過 18 個月才通過，長榮大學原要求所
有人體試驗須經彰基 IRB 通過，省掉自己運作設立 IRB 之經費，可是本計畫被
極端刁難，即使主持人另外一個人簡單取唾液檢體之計畫，也要歷經 14 個月才
能通過彰基 IRB，詢問其他老師也有類似不堪經驗，因此，長榮大學有部份老師
已經嚴重受到彰基 IRB 之百般刁難，進而嚴重影響研究計畫之進行，雖然現在
長榮在老師極端反彈下，終於成立自己的 IRB，但是，傷害已然造成。 
 
研究成果 
一、 英文期刊論文(2005 迄今) 
 8
Author)  (SSCI) 
10. Amanda LC Chen, Thomas JH Chen, et al. (2008) “Hypothesizing that Brain 
Reward Circuitry Genes Are Genetic Antecedents of Pain Sensitivity and 
Critical Diagnostic and Pharmacogenomic Treatment Targets For Chronic Pain 
Conditions.” Medical Hypotheses. (SCI)  
11. Kenneth Blum, Amanda L Chen, Thomas J Chen, et al. (2008) “The H-Wave 
Device and Program is an Effective and Safe Non-Pharmacological Analgesic 
for Chronic Pain: a Meta-Analysis”, Advances in Therapy, 25(7): 644-57. (SCI)  
12. Kenneth Blum, Thomas JH Chen*, et al. (2008) “Dopamine D2 Receptor Taq 
A1 Allele Predicts Treatment Compliance of LG839 in a Subset Analysis of Pilot 
Study in the Netherlands” Gene Therapy & Mol Biology, 12: 129-40. (SCI) 
(Corresponding Author) 
13. Chen, Amanda LC, Kenneth Blum, Thomas JH Chen*, et al. (2008) “The 
Impact of Biomics Technology and DNA Directed Anti-Obesity Targeting of the 
Brain Reward Circuitry” Gene Therapy & Mol Biology, 12: 45-68. (SCI) 
(Corresponding Author) 
14. Meshkin, Brian, Thomas JH Chen, et al. (2008) “Health Economics of 
Nutrigenomics in Weight Management”, Gene Therapy & Mol Biology, 12: 
25-30. (SCI)  
15. Chen, Amanda LC, Chao-Wei Wu, Kenneth Blum, Fengcheng Tang, Thomas 
JH Chen*. (2008) “Mesolimbic Reward Circuitry and Reward Deficiency 
Syndrome (RDS): A Commentary on Long Term Dopaminergic Therapy.” 
Journal of Occupational Safety and Health, 16(1): 1-22.  (Corresponding 
Author) 
16. Chen, Amanda LC, Chao-Wei Wu, San-Ping Ho, Kenneth Blum, Thomas JH 
Chen* (2007) Neurochemical and Clinical Aspects of Acupuncture & 
Auriculotherapy: Adaptation in United States for Substance Use Disorder (SUD), 
A Clinical Subtype of Reward Deficiency Syndrome (RDS), Journal of 
Occupational Safety and Health, 15: 308-332. (Corresponding Author) 
17. Chen, Thomas JH, Kenneth Blum, et al. (2007) Chromium Picolinate (CrP) a 
putative anti-obesity nutrient induces changes in body composition as a function 
of the Taq1 dopamine D2 receptor polymorphisms in a randomized 
double –blind placebo controlled study. Gene Therapy & Mol Biology,11(B): 
161-170.  (SCI). 
18. Braverman, Eric R, Thomas JH Chen, et al. Plasma Growth Hormones, P300 
Event-Related Potential and Test Of Variables of Attention (T.O.V.A.) (2007) 
Are Important Neuroendocrinological Predictors of Early Cognitive Decline in a 
Clinical Setting: Evidence supported by PATH Analysis. Age, 11(11): 1013-1031. 
 10
a Nonpharmacologic Alternative for the Treatment of Chronic Soft-Tissue Injury 
and Neuropathic Pain. Advances in Therapy, 23(5): 739-49.  (SCI） 
29. Braverman, ER, Chen TJH, et al. (2006) Delayed P300 Latency Correlates with 
Abnormal Test Of Variables of Attention ( TOVA) in Adults. Advances in 
Therapy, 23 (4) 582-600. (SCI） 
30. Blum, K, NA DiNubile, TJH Chen, et al. (2006) H Wave: An Alternative 
Nonpharmacologic Approach to Relieving Lower Extremity Pain Caused by 
Osteoarthritis or Injury: A Preliminary Evaluation. Advances in Therapy, 23(3): 446-455. 
(SCI） 
31. Blum, K, TJH Chen, et al. (2006) Nutrigenomics and Pharmacogenomics: a 
Scientific Wonderland. Social Science Information Sur Les Sciences Sociales, 
45(1):35-52. (SSCI) 
32. Reuben, C; TJH Chen; et al. (2005) Acupuncture & Auriculotherapy: Valuable 
Natural Treatment Modalities for Addiction. Townsend Letter for Doctors & 
Patients, 269: 81-84. 
33. Chen, TJH; K Blum, et al. (2005) Are Dopaminergic Genes Involved in a 
Predisposition to Pathological Violence? Hypothesizing the Importance of 
“Super Normal Controls” in Psychiatric Genetic Research of Complex 
Behavioral Disorders. Medical Hypotheses. 65(4): 703-7.（SCI） 
34. Blum, K, TJH Chen & BD Ross. (2005) Innate Properties of H-Wave® Device, 
a Small Fiber Stimulator Provides the Basis for a Paradigm Shift of Electro 
-Therapeutic Treatment of Pain with Increased Functional Restoration 
Associated with Human Neuropathies: a Hypothesis. Medical Hypotheses. 64(5): 
1066-7.（SCI） 
35. Blum, K, TJH Chen & BD Ross. (2005) Innate Properties Of H-Wave® Device, 
A Small Fiber Stimulator Provides The Basis For a Paradigm Shift Of 
Electro-Therapeutic Treatment Of Pain With Increased Functional Restoration 
Associated With Human Neuropathies: A Hypothesis, Townsend Letter for 
Doctors & Patients, January, p. 101-4. 
二、 可供推廣之研發成果資料 
附件八可供推廣之研發成果資料列出本計畫可能可以申請專利之項目，更
進一步的研究，增加樣本數，確立上述基因實驗結果，應可申請專利。 
 12
2.6 您是否有領取社會救濟金 □1.否 □2.是 
三、過動 
3.1 您是否無法持續坐著，手或腳會動來動去坐立不安？ □1.否或不知 □2.偶爾 □3.常常 
3.2 您是否很難待在座位上？ □1.否或不知 □2.偶爾 □3.常常 
3.3 您在睡覺時是否很容易翻來覆去？ □1.否或不知 □2.偶爾 □3.常常 
3.4 您是否常打斷他人說話或突然闖入他人的活動？ □1.否或不知 □2.偶爾 □3.常常 
3.5 您是否常常講太多話？ □1.否或不知 □2.偶爾 □3.常常 
3.6 您是否曾被西醫診斷為過動症病人，而需以藥物控制或治療？ □1.否 □2.是 
四、注意力 
4.1 您是否無法完成已開始做的事？ □1.否或不知 □2.偶爾 □3.常常 
4.2 當有人與您說話時並沒有注意聽？□1.否或不知 □2.偶爾 □3.常常 
4.3 您是否容易抓狂？ □1.否或不知 □2.偶爾 □3.常常 
4.4 您是否很難專心？ □1.否或不知 □2.偶爾 □3.常常 
4.5 您是否很難堅持於一項活動？ □1.否或不知 □2.偶爾 □3.常常 
4.6 您是否很難遵循訓令？ □1.否或不知 □2.偶爾 □3.常常？ 
4.7 您是否常常弄丟家裡或工作上的必需品？ □1.否或不知 □2.偶爾 □3.常常 
五、飲食 
5.1 您是否曾經狂吃過(在短時間內迅速消耗大量食物)？  
□1.否 □2.是  年紀______歲時 
5.1.1 如選「是｣，您是否曾在 3 個月中一個禮拜狂吃兩次？ □1.否 □2.是  年紀______歲時 
5.2. 您是否對下列很渴望 
     a. 糖                      □1.不渴望 □2.中等渴望 □3.非常渴望 
     b. 巧克力                  □1.不渴望 □2.中等渴望 □3.非常渴望 
     c. 甜點或碳水化合物(汽水類) □1.不渴望 □2.中等渴望 □3.非常渴望 
     d. 其他，請說明 _________________□1.不渴望 □2.中等渴望 □3.非常渴望 
5.3 您是否曾認為自己對吃有衝動？ □1.否 □2.是 
5.4 您是否會喝過多的水或其他液體或吃冰？ □1.無 □2.有點 □3.的確如此 
5.5 您是否曾被西醫診斷為肥胖症病人，而需以藥物控制或治療？ □1.否 □2.是 
六、抽煙、吃檳榔 
6.1 您是否曾經抽香菸、雪茄或煙斗超過一個月以上？ □1.否 □2.是 
6.2 如果您現在抽煙，平均一天抽多少？ 
□1.從來沒有(跳答 6.3) □2.每天 1 到 10 支 □3.每天 11 支到一包（20 支） 
□4.每天多於一包 □5.偶而抽幾支 □6.只抽幾次即不抽 
6.2.1 請問您幾歲第一次抽煙？ 
□1.10 歲以下 □2.11~20 歲 □3.21~30 歲 □4.31~40 歲 □5.41 歲及以上 
6.2.2 請問您持續抽幾年了？            年（若中途有中斷幾年，請扣除這幾年） 
6.3 您是否有（或曾經有）嚼食檳榔的習慣？  
□1.從來沒有(跳答 7.1) □2.每天 1 到 10 顆 □3.每天 11 到 20 顆  
 14
□1.無 □2.1~2 人 □3.3~5 人 □4.6 人及以上 
9.4.1 與您同時發生最嚴重的職業災害是否有人死亡? □1.否 □2.是 
9.4.2 與您同時發生最嚴重的職業災害的死亡人數?  
□1.1 人 □2.2~3 人 □3.4~5 人 □4.6 人及以上 
9.4.3 與您同時發生最嚴重的職業災害的輕傷人數?  
□1.1 人 □2.2~3 人 □3.4~5 人 □4.6 人及以上 
9.4.4 與您同時發生最嚴重的職業災害的重傷人數?  
□1.1 人 □2.2~3 人 □3.4~5 人 □4.6 人及以上 
9.5 您在發生職業災害後是否有發生肢體殘障? □1.否 □2.是 
9.6 您的殘障等級：□1.輕度 □2.中度 □3.重度 □4.極重度 
9.7 發生最嚴重的職業災害所造成公司財產損失的程度為？ □1.輕微 □2.中度 □3.嚴重 □4.破產 
9.8 您是否曾因為工作不小心或器械操作不當而造成職業傷害？  
□1.不曾 □2.曾經有過，幾次? □1.0 次 □2.1 到 2 次 □3.3 到 5 次 □4.6 次及以上 
9.8.1 那最嚴重的結果是？  □1.擦藥幾天即好 □2.縫合幾針即好 □3.住院幾天即好  
□4.截肢 □5.半身癱瘓 □6.全身癱瘓 
 
訪視結束的時間：      時      分 
訪視者簽名：_______________ 
受訪者簽名：_______________ 
 16
心管，並離心 1 分鐘，為了完全移除 B5。 
11.將 NucleoSpin tube 置於另一個乾淨的 1.5 ml 離心管，再以 200 μl 的 10Mm 
Tris/Hcl，ph=9（加熱至 70 ℃）萃取 DNA，離心 1 分鐘（6000 xg）。 所得的過
濾液即可去測 OD 定量 DNA。 
頭髮─ Chelex 100  extract DNA 
Prepare: 
1. autoclaved deionized water 
2. 5% Chelex 100  
表 1. 5% Chelex 100 
20%/5% Chelex Solution  
The DNA Extraction Reagent available from Bio-Rad. The 20% Chelex 
Solution will be prepared and can be diluted to 5% with autoclaved deionized water 
Note: When pipetting Chelex stock solutions, the resin beads must be 
distributed evenly in solutions; this can be achieved by gentle mixing with a stir bar 
in beaker. Also, the pipette tip used for transfer must have a large bore. One ml 
pipette tips are adequate. 
3.10mg/mL Proteinase K 
表 2. 10mg/mL Proteinase K 
若取別種濃度的 Proteinase K 則需配置 10mg/mL 的濃度才可用 
 
 18
To extract DNA : 
表 4. To extract DNA(Oral Swbs) 
Step Action 
1. Suspend the swab sample in 1mL of autoclaved deionized water in an autoclaved 
1.5-mL microcentrifuge tube.  
2. Incubate at room temperate for 30 minutes.  
3. Twirl the swab and toothpick for 2 minutes to release the cells from the swab. 
4. Remove the substrate and toothpick. Spin in a microcentrifuge for 2 minutes at 
10000-15000xg（maximum speed ）at room temperature. 
5. Without disturbing the pellet, remove and discard all but 25 μl (or twice the 
volume of the pellet, whichever is greater ) of the supernatant. 
6. Resuspend the pellet in the remaining 25μl by stirring with an autoclaved 
pipette tip. 
7. Add 200μl of 5% chelex in a 1.5-ml microcentrifuge tube. 
8. Add 2μl of 10mg/ml proteinase K.  Mix . 
9. Incubate the sample at 56℃ for15-30 minutes. 
10. Vortex 5-10 seconds. 
11.   Spin down 10-20 seconds. 
12. Boiling water bath for 8 minutes. 
13. Vortex 5-10 seconds 
14. Spin the sample in a microcentrifuge for 2-3 minutes at 10,000-15,000xg 
(maximum speed) at room temperature. The sample is now ready for DNA 
quantitation and the PCR amplification process. 
15. Store the remainder of the sample at either 2-6℃ or –15 to –25℃. 
16. To reuse, thaw sample at room temperature and repeat steps 7-8. 
 20
附件三、選定之基因 
（1） 5 HT 2A (5-hydroxytryptamine 2A) receptor gene 
Genotyping of the T/C polymorphism at position 102 of HTR2A was done by 
polymerase chain reaction (PCR) (Bondy et al., 2000) using the primers of 
5’-TCTgCTACAAgTTCTggCTTT-3’, and 5’-CTgCAgCTTTTTCTCTAggg-3’. PCR was 
performed in a final volume of 25 l consisting of 50 ng DNA, 0.6 M of each primer, 　 　
200 M dNTPs, 10 mM Tris　 -HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl2, and 1.25U Taq 
polymerase. Annealing was carried out at 60℃ for 30 sec, extension at 72℃ for 30 sec, 
and denaturation at 95℃ for 30 sec for 35 cycles. PCR products were digested with 10 U 
Msp I (Roche) for 14 hr and separated on a 2% agarose gel (FMC NuSieve 3:1). The 
102T-allele (T102) showed a PCR product fragment of 342 bp and the 102C-allele (C102) 
showed two PCR product fragments of 126 bp and 216 bp after digestion with restriction 
enzyme of MspI. The laboratory personnel was blind to the origin and diagnoses of the 
DNA probes.  
（2） 5-HTTLPR (serotonin transporter promoter region polymorphism) 
gene 
An insertion/deletion polymorphism has been reported in the promoter region 
(5HTTLPR) (Heils et al., 1996). The polymorphism consists of two allelic forms and is 
associated with different 5-HTT promoter activity. The allele designated “l” has greater 
transcriptional activity and subsequently more serotonin reuptake than the short allele “s”, 
which is associated with a more restricted transcriptional activity of the promoter leading 
to lower functional expression of the 5 HTT (Heils et al., 1996). 
The 5-HTTLPR-promoter region polymorphism was characterized as described by 
Ebstein et al. (1997) and Manor et al. (2001). Polymerase chain reaction (PCR) 
amplification was performed by using Taq Polymerase and a high denaturing temperature 
(98 ℃ ). The primers used to generate a 484/528-bp fragment were SIL-1 
5’-ggCgTTgCCgCTCTgAATgC-3’ and SIL-2 5’-gAgggACTgAgCTggACAACCAC-3’. 
The reaction mixture contains the following components: 1 x reaction buffer, 0.5 M 　
primers, 100 ng DNA, 200 M dATP, dTTP, dCTP, 100 M dGTP, and 100 M 　 　 　
7-deaza-2’-dGTP, 1 U Taq Polymerase, and 12 % DMSO in a total volume 15 L. After 　
an initial denaturation step of 95℃ for 2.5 min, amplification was performed for 40 
cycles (95℃ for 45 sec, 55℃ for 45 sec, and 72℃ for 90 sec) in a extension at 72℃ 
was used. The reaction mixture was electrophoresed on a 2% agarose gel with ethidium 
 22
for 4 hr and analyzed by using a 2% ethidium bromide-stained agarose gel. The digested 
products of 502 bp were type “C”, and that of 457 bp and 45 bp were type “T”. 
（5）ADRA2R ( 2a adrenergic receptor gene)　  
The genotyping of the biallelic polymorphism in the promoter region of the 2a 　
adrenergic receptor gene (ADRA2R) was conducted according to a protocol described by 
Lario et al. (1997). A 522-bp fragment from the promoter region of the ADRA2R gene 
was amplified by PCR using a sense primer (5’-TCACACCggAggTTACTTCCCTCg-3’) 
at position –1417 upstream from the putative origin of the transcription site and an 
antisense primer (5’-TCCgACgACAgCgCgAgTT-3’) at position –913. The PCR reaction 
mixture contained 0.2 mM dNTP, 1.0 mM MgCl2, 1 M of each primer. After initial 　
denaturation at 94℃ for 1 min, 35 cycles of PCR reaction were performed under 
conditions of 94℃ for 30 sec, 60℃ for 45 sec, and 72℃ for 1 min. The PCR products 
were digested with 2 units of MspI at 37℃ for 2 hr and analyzed by using a 10% 
nondenaturing polyacrylamide gel and then stained by using ethidium bromide. The 
samples with digested products of 174, 165, 116, 62, and 5 bp were typed as “M”. The 
transversion C->G produces the loss of the 174bp fragment appearing two polymorphic 
bands of 121 and 53 bp that determine the allele “m” ( 121,53,165,116,62, and 5 bp ). 
（6）COMT (catechol-O-methyltransferase) 
COMT is a ubiquitous enzyme that catalyzes the O-methylation of several 
catecholamine neurotransmitters, including dopamine, epinephrine, and norepinephrine. 
The enzyme exists in two forms (thermolabile, thermostable) that functionally differ by a 
3-4 –fold variation in enzyme activity. The gene for COMT contains a known Nla III 
restriction fragment length polymorphism (RFLP) at codon 158 where a nucleotide 
transition causes a change in the amino acid sequence (Val -> Met). 
The COMT val/met genotype polymorphism was performed via PCR-based 
restriction analysis as described by Daniels et al. (1996). The primers were 
5’-ACTgTggCTACTCAgCTgTg-3’ and 5’-CCTTTTTCCAggTCTgACAA-3’. The 
reaction mixture consisted of the following components in a total volume of 15 l  　
(100 ng DNA, 2.5 mM MgCl2, 250 M dNTPs, 0.25 M of each primer, 1.5 units Taq 　 　
Polymerase). Initial denaturation was carried out for 5 min at 94℃ and was followed by 
30 cycles of 94℃ for 45 sec, 60℃ for 1min, and 72℃ for 1 min; final extension was at 
72 ℃ for 10 min. The entire PCR product was digested with 10 units of Nla III enzyme 
(New England Biolabs) and incubated at 37℃. Digestion products were separated on 6% 
nondenaturing polyacrylamide gel that was stained with ethidium bromide and observed 
 24
表 5 Primers used for PCR amplification of CYP2A6 
Primer name                              sequence 
2A6-Ex3In    5’-AAC CTG ATC GAC TAG GCG TGG TA-3’ 
2A6-Ex4R    5’-GGA GGT TGA CGT GAA CTG GAA GA-3’ 
E3F     5’-GCG TGG TAT TCA GCA ACG GG-3’ 
E3R     5’-TCG TCC TGG GTG TTT TCC TTC-3’ 
 
（8）DAT 1 gene 
The alleles at the 3’UTR were determined by PCR using the oligomers and PCR 
conditions reported by Vandenbergh et al., (1992). Following PCR amplification the 
products were electrophoresed in an 8% acrylamide gel with a set of size markers.  
（9）DRD2 gene 
A. Introduction  
The dopaminergic system, and in particular the dopamine D2 receptor, has been 
profoundly implicated in reward mechanisms in the brain. Dysfunction of the D2 
dopamine receptors leads to aberrant substance seeking behavior (alcohol, drug, tobacco, 
and food) and other related behaviors (pathological gambling, Tourette’s syndrome, and 
attention deficit hyperactivity disorder).  
B. Genotype determination 
Blood samples were collected with EDTA anticoagulant, and genomic DNA was 
extracted from leukocytes using NucleoSpin Blood Isolation Kit (Macherey-Nagel,  
Gmbh & Co. KG.) 
Restriction fragment length polymorphism (RFLP) analysis of Taq I A 
polymorphism of the DRD2 gene was carried out by using a PCR-based restriction 
analysis according to the method described by Grandy et al. (1993), with modifications. 
In brief, amplification reactions were carried out in a volume of 50 l, containing 100ng 　
genomic DNA as template, 200 M dNTP, 1 M of each sense and antisense pr　 　 imer, 1 X 
 26
A1 allele” refers to the gene frequency where the total number of DRD2 A1 alleles are 
counted and divided by the total number of haploid sets of chromosomes.  
（10）DRD3 gene  
Genotype determination： 
Blood samples were collected with EDTA anticoagulant, and genomic DNA was 
prepared using Resin extraction method (Promega, ). 
Restriction fragment length polymorphism (RFLP) analysis of Msc I  
polymorphism of the DRD3 gene was carried out by using a PCR-based restriction 
analysis according to the method described by Legro et al. (1995). Primers were designed 
flanking the polymorphic site in the first exon of the D3 receptor gene. The sequence of 
sense (DRD3-1) and antisense (DRD3-2) primers were 
5’-GGGCTATGGCATCTCTGAGT-3’ and 5’-AAGTAGTTGGTGGTAGTCTG-3’, 
respectively. Polymerase chain reaction was performed using 200ng of DNA. The 
reaction mixture had final concentration of 50 mM KCl, 10 mM Tris HCl pH8.3, 1.5mM 
MgCl2, 0.005% Tween 20, 0.005% NP-40, 0.1 mM of each primer, and 0.5U of 
AmpliTaq. After a initial denaturation step for 5 minutes at 95℃ , 30 cycles of 
amplification were performed using a Perkin Elmer thermal cycler with 1 minute at 95℃, 
1 minute at 50℃, and 1 minute at 72℃.  
Restriction endonuclease digestion was performed adding 2U of Msc I (New 
England Biolabs, Beverly, MA) and incubating at 37℃ for 6 hours. After digestion, 
fragments were sized on a 10% polyacrylamide gel at 120V for 4 hours in a vertical gel 
electrophoresis apparatus. Gels were then strained with ethidium bromide, destained in 
sterile water, and visualized with ethidium bromide staining under ultraviolet light. 
The product of the polymerase chain reaction was 204 bas pairs (bp). The 
polymorphism in the receptor gene results in an adenine (A) to guanine (G) substitution. 
This A to G change, creats an additional MscI restriction enzyme cleavage site in the 
amplified segment. The other cleavage site is downstream such that allele 1 or the 
wild-type (the most frequently occurring allele) would have two fragments after Msc I 
digestion: 128bp and 76bp, the 2 allele or mutant type ( in this case the less common 
allele) would have three fragments: 98, 76 and 30 bp. The second cleavage site present in 
both alleles serves as an internal control to verify the efficacy of the restriction enzyme. 
（11）DRD4  
 28
A dinucleotide repeat polymorphism at the DRD5 gene, D5(CT/GT/GA)n were 
studied as described by Sherrington et al. (1993). For amplification of the microsatellite, 
the primers were  designed as DRD5-1 (5’-CgTgTATgATCCCTgCAg-3’) and DRD5-2 
(5’-gCTCATgAgAAgAATggAgTg-3’). For the amplification, primer DRD5-2 was 
labeled with 32P using T4 polynucleotide kinase. Each reaction contained 1 pM of each 
primer and used an annealing temperature of 58℃. The PCR products were then 
separated by a 4% sequencing gel and DRD5(CT/GT/GA)n  repeat alleles were revealed 
by autoradiography. Twelve repeat alleles were found, here designated as : allele 1 (156 
bp), allele 2 (154 bp), allele 3 (152 bp), allele 4 (150 bp), allele 5(148 bp), allele 6 (146 
bp), allele 7 (144 bp), allele 8 (142 bp), allele 9 (140 bp), allele 10 (138 bp), allele 11 
(136 bp), allele 12 (134 bp). 
（13）GABRA3 (　-aminobutyric acid A3) receptor gene  
A dinucleotide repeat polymorphism, at GABRA3 was used for the genetic studies 
(Gade-Andavolu R et al., 1998). The amplified product size ranged from 161 bp to 171 
bp and the primers annealed to the CA and GT strands. Polymerase chain reaction was 
used to amplify the target DNA, using 0.1 M of each　  fluorescence-labeled primer 
5’-gggTTCAggAgACTgCACAgCAA-3’ and 5’-TCCTgAgggCAgggTCTCTgA-3’ in 
separate reactions. 0.5 l of the Polymerase chain reaction product added to 2.8 L of a 　 　
mixture of 50 l of deionized formamide plus 5 l of internal standard (R　 　 OX500, 
Applied Biosystem Inc.) plus 5 l of blue dextran dye, then denatured for 2 seconds at 　
92℃ . The sample was loaded on a 6% polyacrylamide gel electrophoresis DNA 
sequencer (373 DNA sequencer) and gel was run for 5 hours at 1500 V with a constant of 
30W. The gel was preprocessed and analyzed using the internal standard (ROX500). Two 
peaks were recognized by software (Genotyper, version 1.1, Applied Biosystem Inc) 
based on the color and the size of the fragment. 
（14）GABRB3 (　-aminobutyric aicd A3 receptor 3 subunit)　  
The 　-aminobutyric aicd (GABA) system has been implicated in the anxiolytic 
(Liljequist and Engel, 1984; Suzdak et al., 1986; Koob et al., 1988), intoxicating (Frye 
and Breese, 1982; Liljequist and Engel, 1982; Suzdak et al., 1986) and reinforcing (Fadda 
et al., 1983; Rassnick et al., 1993; Hodge et al., 1995) effects of ethanol. GABA, the 
major inhibitory neurotransmitter in the mammalian brain, exerts its main actions through 
GABAA receptors, hetero-oligomeric ligand-gated chloride channels that are encoded by 
at least 15 separate subunit genes. Deletion of 3, 5 and 3 genes and surrounding 　 　 　
loci result in neurological dysfunction and physical abnormalities in both animals 
(Nakatsu et al., 1994; Culiat et al, 1994, 1995) and humans (Angelman syndrome) 
 30
（16）HTR1A gene polymorphism 
The defects in the serotonin 5-HT1A receptor have been implicated as playing a 
major role in anxiety, depression and other psychiatric disorders (Hamon, 1997). This 
makes the HTR1A gene an important candidate gene for psychiatric genetics.  
The C—1018G variant in the region of the promoter sequences of 5-HT1A receptor 
gene was detected by polymerase chain reaction (PCR) as described by Wu and Comings 
(1999). PCR amplification was carried out in a total volume of 20 l containing 50 ng of 　
genomic DNA, 150 nM of each primer, 150 M dNTPs, 3.5 mM MgCl2. The 　
amplification was performed for 30 cycles with denaturation at 95℃  for 30 sec, 
annealing at 62℃ for 40 sec and elongation at 72℃ for 40 sec. The amplified product 
was the digested with DdeI and the resulting polymorphic fragments were separated on a 
10% polyacrylamide gel and stained with ethidium bromide. This identified two alleles: 
G 174 bp, and C:152 + 22bp. The primers were 5’-CTgAgggAgTAAggCTggAC-3’ and 
5’-gAAgAAgACCgAgTgTgTCCTA-3’. 
（17）INFG (interferon-gamma) gene 
Gamma interferon plays an important role in the genetic regulation of 200 genes 
(Boehm et al., 1997) including many that are of potential importance in psychiatric 
disorders. 
The G5644 polymorphism in the INFG gene was detected using PCR-based 
restricted enzyme digestion method as described by Wu et al. (1998). A special-purpose 
primer was designed as followed: INFG-1 5’-CTAAgTgAgACCTggAgTg-3’ and INFG-2 
5-‘AgggAgAggAAgATTCTgACA-3’. (by changing an oligonucleotide base at the 3’-end 
second position in the INFG-2 a NlaIII restriction site was generated in the A allele. PCR 
amplification was carried out in a total volume of 25 l containing 50 ng of genomic 　
DNA, 2 pmol of each primer, 100 M dNTPs,  1.5 mM MgCl2. The amplification was 　
performed for 30 cycles with denaturation at 94℃ for 1 min, annealing at 60℃ for 1 
min and elongation at 72℃ for 1 min. The amplified product was then digested with 
NlaIII and the resulting polymorphic fragments were separated on a 10% polyacrylamide 
gel in 1 x TBE buffer. This identifies two alleles: allele G: 324 bp, and allele A: 304 bp 
+20 bp. 
（18）-opioid-receptor gene (OPRM1) A118G  
Genotyping was performed as described by Bergen et al. (1997).  
 32
附件四、130 個實驗分析結果 
  
Figure 1 The Polymerase chain reaction (PCR) amplification of region downstream from 
the polyadenylation signal, restriction digest with Taq I and electrophoresis on a 3% 
agarose gel. The far lane on the left has a X174 DNA/Hae III　  marker. Lane 1 is 
homozygous for A1/A1, lane 2 is heterozygous A1/A2, lane 3 is homozygous for A2/A2. 
 
 
1,353
1,078
872
603
310
281/271
234
194
118(72)
M 1     2     3    4      5     6  
bp
Gene:Gβ3
1
C
Frequency 57.69% 42.31%
39 19
14.62%
Table.7 Prevalence of T/T, T/C, and C/C genotypes
( 130)
Genotypes T/T T/C C/C
Number
                                Table.8  Frequency ofthe T and C allele. (n=260)
Allele T
72
Prevalence 30.00% 55.38%
 34
 
1,353
1,078
872
603
310
281/271
234
194
118(72)
1     2     3     4     M 
bp
Gene:ADA
118
Figure.3 : The ADA locus encompasses 12 exons spanning approximately 32 Kb and is
located on chromesome 20q 13.11 . The Polymerase chain reaction (PCR) amplification
polymorphism signal, the presence of the ADA2 mutation determines the loss of  restric
M/N N/N
90.77%
                     Table.11  Prevalence ofM/M, M/N, and N/N genotypes (n=130)
Number 0 12
Prevalence 0.00% 9.23%
Genotypes M/M
Table.12 Frequency ofthe M and N allele.
( 260)
Allele M
Frequency 4.62% 95.38%
N
 36
 
1,353
1,078
872
603
310
281/271
234
194
118(72)
M 1   2   3 
bp
Gene:DRD2β
45
35.71%
                   Table.15  Prevalence of B1/B1, B1/B2, and B2/B2 genotypes (n=126)
Number 21 60
Prevalence 16.67% 47.62%
Figure.5 : The Polymerase chain reaction (PCR) amplification of region downstream from
the polyadenylation signal, restriction digest with Taq I and electrophoresis on a 3% agarose
gel. The far lane on the left has a fX174 DNA/Hae III marker. Lane 1 is h
Genotypes B1/B1 B1/B2 B2/B2
Table.16 Frequency ofthe B1 and B2 allele.
( 252)
Allele B1
Frequency 40.48% 59.52%
B2
 38
 
726
713 
553 500
427/417/413
311
249
200
151
140
118
100
82
M       1    2       3       4Gene:COMT
C
Frequency 70.54% 15.50%
Table.20  Frequency ofthe H and L allele.
( 258)
Allele H L
17.05% 6.98%
Number 80 22 9
Prevalence 62.02%
                     Table.19  Prevalence of H/H, H/L, and L/L genotypes (n=129)
Genotypes H/H H/L L/L
Figure.7 : The Polymerase chain reaction (PCR) amplification of exon 4 of the COMT
gene, which falls within the region of chromosome 22q11, restriction digest with NlaⅢ
electrophoresis on 3.5% agarose gel. The far lane on the left has a fX174 DNA/HinfⅠma
 40
 
 
Gene:DRD3 M   1    2     3     4     5    6
726
713
553 500
427/417/413
311
249
200
151140 118
100
82
66
48/42/40
24
                    Table.23  Prevalence of A/A, G/G and A/G genotypes (n=129)
A
72
Figure.9 : The Polymerase chain reaction (PCR) amplification of region downstream from
the polyadenylation signal, restriction digest with Msc and electrophoresis on 8%
polyacrylamide gel. The far lane on the left has a f174 Hinf1 marker. Lane 1 and 2 ar
Genotypes A/GG/GA/A
Number 489
Frequency 25.58%74.42%
37.21%6.98%Prevalence 55.81%
Table.24 Frequency of the A and G allele.
( 258)
Allele G
 42
Chong SA, Tan EC, Tan CH, Mahendren R, Tay AHN, and Chua HC. Tardive dyskinesia is 
not associated with the serotonin gene polymorphism (5-HTTLPR) in Chinese.2000. Am J Med 
Gen (Neuropsych Genet) 96:712-715. 
Cloninger CR, Adolfsson R, Svrakic NM. 1996. Mapping genes for human personality. Nat 
Genet 12:3-4.  
Cloninger CR, Svrakic DM, Przybeck TR. 1993. A psychobiological model of temperament 
and character. Arch Gen Psychiatry 50:975-990. 
Comings DE, Comings BG, Muhleman D, Dietz G, Shahbahrami B, Tast D Knell E, Kocsis 
P, Baumgarten R, Kovacs BW, Levy DL, Smith M, Kane JM, Leiberman JA, Klein DN, 
MacMurray J, Tosk J, Sverd J, Gysin R, Flanagan S. The dopamine D2 receptor locus as a 
modifying gene in neuropsychiatric disorders. J Am Med Assn 1991; 266:1793-1800. 
Comings DE, Flanagan SD, Dietz G, Muhleman D, Knell E, Gysin R. 1993. The dopamine 
D2 receptor as a major gene in obesity and weight. Biochem Med Metabol Biol 50:176-185. 
Comings DE, Gonzalea N, Wu S, Gade R, Muhleman D, Saucier G, Johnson P, Verde R, 
Rosenthal RJ, Lesieur HR, Rugle LJ, Miller WB, and MacMurray JP. Studies of the 48 bp repeat 
polymorphism of the DRD4 gene in impulsive, compulsive, addictive begaviors: Tourette 
syndrome, ADHD, Pathological gambling, and substance abuse. Am J Med Gen (Neuropsych 
Genet) 1999; 88:358-368. 
Comings DE, Muhleman D and Gysin R. Dopamine D2 receptor (DRD2) gene and 
susceptibility to posttraumatic stress disorder: a study and replication. Biol Psychiatry 1996; 
40:368-372. 
Comings DE, Muhleman D, Dietz G Dino M, LeGro R, Gade R Association between 
Tourette’s syndrome and homozygosity at the dopamine D3 receptor gene. Lancet 1993; 341:906. 
Comings DE, Wu H, Chiu C, Ring RH, Dietz G, Muhleman D. Polygenic inheritance of 
Tourette syndrome, stuttering, ADHD, conduct and oppositional defiant disorder: the additive and 
subtractive effect of the three dopaminergic genes – DRD2, D H and DAT1. Am J Med Gen 　
(Neuropsych Genet) 1996; 67:264-288. 
Culiat CT, Stubbs LS, Montgomery CS, Russell LB, R5inchik EM. 1994. Phenotypic 
consequences of the deletion of the 3, or subunit of the type A aminobutyric 　 　　　 　　 　　　
acid receptor in mice.Proceedings of the National Academy of Sciences USA 91,2815-2818.  
Culiat CT.Stubbs LJ,Woychik RP.Russell LB.Johnson DK.Rinchik EM 1995.Deficiency of 
the 3 subunit of the type A aminobutyric acid receptor causes cleft palate in mice.Nature 　 　　
Genetics 11,344-346. 
Daniels JK, Williams NM, Williams J, Jones LA, Cardon AG, Murphy KC, Spurlock G, 
Riley B, Scambler P, Asherson P, McGuffin P, Owen MJ. 1996. No evidence for allelic 
association between schizophrenia and a polymorphism determining high or low catechol 
O-methyltransferase activity. Am J Psychiatary 153: 268-270.  
DeLorey T,Minassian B,Tydale R,Olsen R 1996.Does the GABAA recepor have a role to 
play in Angelman syndrome?In:Tanaka C,Bowery N(Eds),GABA receptor,Transsporters and 
Metabolism. Basel, Birkhauser, pp 275-282. 
Du L, Bakish D, Lapierre YD, Ravindran AV, Hrdina PD. 2000. Association of 
 44
Horowitz R, Kotler M, Shufman E, Aharoni S, Kremer I, Cohen H, and Ebstein, RP. 
Confirmation of an excess of the high enzyme activity COMT val allele in heroin addicts in a 
family-based haplotypes relative risk study. 2000. Am J Med Genet (Neuropsych Genet) 
96:599-603. 
Klinteberg BA, Magnusson D. 1989. Aggressiveness and hyperactive behavior as related to 
adrenaline excretion. Special Issue: personality and aggression. Eur. J. Personality 3:81-93. 
Lahoste GJ, Swanson JM, Wigal SB, Glabe C, Wigal T, King N, Kennedy JL. Dopamine D4 
receptor gene polymorphism is associated with attention deficit hyperactivity disorder. Mol 
Psychiatry 1996; 1: 121-124. 
Lannfelt L, Sokoloff P, Martres MP, Pilon C. Amino acid substitution in the dopamine 
D-sub-3 receptor as a useful polymorphism for investigating psychiatric disorders. Psychiatr 
Genet 1992; 2: 249-256. 
Lario S, Calls J, Cases A, Oriola J, Torras A, Rivera F. 1997. MspI identifies a biallelic 
polymorphism in the promoter region of the alpha 2A-adrenergic receptor gene. Clin Genet 
51:129-130. 
Lawford BR, Young RM, Noble EP, Sargent J, Rowell J, Shadforth S, Zhang X, and Ritchie 
T. The D2 dopamine receptor A1 Allele and opioid dependence: Association with heroin use and 
response to methadone treatment. 2000.Am J Med Gen (Neuropsychiatric genetics) 96:592-598. 
Legro RS, Lobo RA, Muhleman DR, Kovacs BW, Comings DE. A dopamine D3 receptor 
genotype is associated with hyperandrogenic chronic anovuoation and Fertility and sterility. 1995; 
63(4):779-784. 
Li T, Zhu ZH, Liu X, Hu X, Zhao J, Sahm PC,Collier DA. Association analysis of 
polymorphism ib tge DRD4 gene and heroin abuse in Chinese subjects. 2000. Am J Med Gen 
(Neuropsychiatric genetics) 96:616-621. 
Li T, Zhu ZH, Liu X, Hu X, Zhao J, Sham PC, and Collier DA. Association analysis of 
polymorphisms in the DRD4 gene and heroin abuse in Chinese subjects. Am J Med Gen 
(Neuropsychiatric genetics) 2000; 96:678-683. 
Lichter JB, Barr CL, Kennedy JL, Van Tol HH, Kidd KK, Livak KJ. 1993. A hypervariable 
segment in the human dopamine receptor D4 (DRD4) gene. Hum Mol Genet 2:767-773. 
Liljequist S,Engel JA 1984.The effects of GABA and benzodiazepine receptor antagonists in 
anti-conflict action of diazepam or ethanol.Pharmacology,Biochemistry and Behavior 
21,521-525. 
Liljequist S,Engel T 1982.Effects of GABAergic agonists and antagonists on various 
ethanol-induced behavioral changes.Psychopharmacology 78,71-77. 
Manor I, Eisenberg J, Tyano S, Sever Y, Cohen H, Ebstein RP, and Kotler M. Family-based 
association study of the serotonin trnasporter promoter region polymorphism (5-HTTLPR) in 
attention deficit hyperactivity disorder. 2001. Am J Med Gen (Neuropsychiatric genetics) 
105:91-95. 
Minassian BA,DeLoery T,Olsen R, Bryanat A, Homanics G, Firestone L,Skinner 
S,Handforth A, Nasataourian A, Delgado-Escueta A 1996.GABRB3:a gene involved in 
epilepsy of Angelman Syndrome(AS).Ameriacan Journal of Human Genetics 59,A273. 
 46
Vanyukov MM, Moss HB, Gioio AE, Hughes HB, Kaplan BB, Tarter RE. 1998. An 
association between a microsatellite polymorphism at the DRD5 gene and the liability to 
substance abuse: pilot study. Behav Genet 28:75-82. 
Warren JT Jr, Peacock ML, Rodriguez LC, Fink JK. 1993 An MspI polymorphism in the 
human serotonin receptor gene (HTR2A): detection by DGGE and RFLP analysis. Hum Mol 
Genet 2:338. 
Wu S and Comings DE. 1999. A common C-1018G polymorphism in the human 5-HT1A 
receptor gene. Psychiatric Gen 9: 105-106. 
Wu S, Comings DE. Two single nucleotide polymorphisms in the promoter region of the 
human phenylethanolamine N-methyltransferase PNMT gene. 1999, Psychiatric Gen 9: 187-188. 
Zabetian CP, Gelernter J, and Cubells JF. Functional variants at CYP2A6: New genotyping 
methods, population genetics, and relevance to studies of tobacco dependence. 2000. Am J Med 
Gen (Neuropsychiatric genetics) 96:638-645. 
 48
DRD4 DRD4-1 5’-GCGACTACGTGGTCTACTCG-3’ Lichter et 
al., 1993 
PCR and 
agarose gel 
or maybe
DRD4-2 5’-AGGACCCTCATGGCCTTG-3’ 
DRD5 DRD5-1 5’-CgTgTATgATCCCTgCAg-3’  Sherrington 
et al., 1993 
PCR and 
32P-labeled 
primer
DRD5-2 5’-gCTCATgAgAAgAATggAgTg-3’ 
PNMT PNMT-148-1 5’-CgggACAAgTACggAgCC-3’  Wu and 
Comings,19
99 
PCR and 
MspI PNMT-148-2 5’-CCATCTCCCTTAgTgTCC-3’ 
PNMT-353-1 5’-gTCTCCACCTCgAATCAg-3’ PCR and 
Mnl I PNMT-353-2 5’-CCATCTCTCTTCTCCAgC-3’ 
DRD3 DRD3-1 5’-GGGCTATGGCATCTCTGAGT-3’  Legro et al., 
1995 
PCR and 
MscI DRD3-2 5’-AAGTAGTTGGTGGTAGTCTG-3’ 
GABRB3 GABRB3-1 5’-CTCTTgTTCCTgTTgCTTTCAATACAC-3’ Mutirangura 
et al., 1992 
32P-labled 
primer, PCRGABRB3-2 5’-CACTgTgCTAgTAgATTCAgCTC-3’ 
HTR1A HTR1A-1 5’-CTgAgggAgTAAggCTggAC-3’   Wu and C 
omings, 
(1999)
PCR and 
DdeI HTR1A-2 5’-gAAgAAgACCgAgTgTgTCCTA-3’ 
GABRA3 GABRA3-1 5’-gggTTCAggAgACTgCACAgCAA-3’  Gade-Anda
volu et al., 
(1998)
PCR and 32P or 
fluorescence-l
abeled primer
GABRA3-2 5’-TCCTgAgggCAgggTCTCTgA-3’ 
ADRA2R ADRA2R-1 5’-TCACACCggAggTTACTTCCCTCg-3’ Lario et al. 
(1997) 
PCR and 
MspI ADRA2R-2 5’-TCCgACgACAgCgCgAgTT-3’ 
ADRA1R 
‘ 
ADRA1R-1 5’-ATgCTCCAgCCAAgAgTTCA-3’ Tsai et al., 
(2001) 
PCR and 
PstI ADRA1R-2 5’-TCCAAgAAgAgCTggCCTTC-3’ 
 
 50
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure.11  : The ADA locus encompasses 12 exons spanning approximately 32 Kb and 
is located on  chromesome 20q 13.11 . The Polymerase chain reaction (PCR) 
amplification  polymorphism signal, the presence of the ADA2 mutation determines the 
loss of  restriction digest with Taq 1 and electrophoresis on 3% agarose gel. The far lane 
on the right has a fX174 DNA/HaeⅢ marker. Lane 1, 2 are PCR products, lane 3  is 
heterozygous for  M/N, and lane 4 is homozygous for N/N. In our experiments, we 
didn't find homozygous genotype for M/M. 
 
Table.27 Prevalence of M/M, M/N, and N/N genotypes (n=8) 
Genotypes M/M M/N N/N 
Number 0 0 8 
Prevalence 0.00% 0.00% 100.00% 
 
Table.28 Frequency ofthe M and N allele. (n=16) 
Allele M N 
Frequency 0.00% 100.00% 
1,353
1,078
872
603
310
281/271
234
194
118(72)
1     2     3     4     M 
bp
Gene:ADA
 52
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure.13  : The Polymerase chain reaction (PCR) amplification of region downstream 
from the polyadenylation signal, restriction digest with Taq I and electrophoresis on a 3% 
agarose gel. The far lane on the left has a fX174 DNA/Hae III marker. Lane 1 is 
homozygous for B1/B1, lane 2 is heterozygous B1/B2, lane 3 is homozygous for B2/B2. 
 
Table.31 Prevalence of B1/B1, B1/B2, and B2/B2 genotypes (n=8) 
Genotypes B1/B1 B1/B2 B2/B2 
Number 0 7 1 
Prevalence 0.00% 87.50% 12.50% 
 
Table.32 Frequency ofthe B1 and B2 allele. (n=16) 
Allele B1 B2 
Frequency 43.75% 56.25% 
 
 
 
1,353
1,078
872
603
310
281/271
234
194
118(72)
M 1   2   3 
bp
Gene:DRD2β
 54
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure.15  : The Polymerase chain reaction (PCR) amplification of exon 4 of the COMT 
gene, which falls within the region of chromosome 22q11, restriction digest with NlaⅢ 
electrophoresis on 3.5% agarose gel. The far lane on the left has a fX174 DNA/HinfⅠ
marker. Lane 1 is the product of the Polymerase chain reaction (PCR). Lane 2 are 
homozygous for H/H, lane 3 are heterozygous for  H/L, and lane 4 are homozygous for 
L/L . 
 
Table.35 Prevalence of H/H, H/L, and L/L genotypes (n=8) 
Genotypes H/H H/L L/L 
Number 6 1 1 
Prevalence 75.00% 12.50% 12.50% 
 
Table.36 Frequency ofthe H and L allele. (n=16) 
Allele H L 
Frequency 81.25% 18.75% 
 
 
726
713 
553 500
427/417/413
311
249
200
151
140
118
100
82
M       1    2       3       4Gene:COMT
C
